Role of ω3 longchain polyunsaturated fatty acids in reducing cardio-metabolic risk factors

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 11, Issue 3, 2011, Pages 232-246

  Abeywardena, Mahinda Y ^a   Patten, Glen S ^a  

^a CSIRO   (Australia)

Author keywords

Cardiovascular disease; Diabetes; Endothelium; Hypertension; Inflammation; Insulin resistance; Metabolic syndrome

Indexed keywords

ARACHIDIC ACID; ARACHIDONIC ACID; C REACTIVE PROTEIN; CERVONIC ACID; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; FISH OIL; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; LAURIC ACID; LIGNOCERIC ACID; LINOLEIC ACID; LINOLENIC ACID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYRISTIC ACID; OLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PALMITIC ACID; POLYUNSATURATED FATTY ACID; STEARIC ACID; STEARIDONIC ACID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VACCENIC ACID;

ATHEROGENESIS; BLOOD PRESSURE; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; DIABETES MELLITUS; DIET; DIET SUPPLEMENTATION; DYSLIPIDEMIA; FATTY ACID METABOLISM; FATTY ACID SYNTHESIS; FOOD INTAKE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; MICROVASCULAR ENDOTHELIAL CELL; MOLECULAR MECHANICS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARTICLE SIZE; REVIEW; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79961087435     PISSN: 18715303     EISSN: 18715303     Source Type: Journal    
DOI: 10.2174/187153011796429817     Document Type: Review

References (174)

1. World Health Organization: The global burden of disease - 2004 update. WHO, Geneva, Switzerland, 2008.
2. Mendis, S. (2010) The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: a global perspective. Prog. Cardiovasc. Dis., 53, 10-14.
3. Yusuf, S.; Reddy, S.; Ounpuu, S. and Anand, S. (2001) Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation, 104, 2746-2753.
4. Abeywardena, M.Y. (2003) Dietary fats, carbohydrates and vascular disease: Sri Lankan perspectives. Atherosclerosis, 171, 157-161.
5. Yusuf, S.; Hawken, S.; Ounpuu, S.; Dans, T.; Avezum, A.; Lanas, F.; McQueen, M.; Budaj, A.; Pais, P.; Varigos, J.; Lisheng, L. and INTERHEART Study Investigators. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 364, 937-952.
6. Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; Donato, K.A.; Eckel, R.H.; Franklin, B.A.; Gordon, D.J.; Krauss, R.M.; Savage, P.J.; Smith, S.C. Jr.; Spertus, J.A.; Costa, F.; American Heart Association; National Heart, Lung, and Blood Institute. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112, 2735-2752.
7. Carpentier, Y.A.; Portois, L. and Malaisse, W.J. (2006) n-3 fatty acids and the metabolic syndrome. Am. J. Clin. Nutr., 83, 1499-1504.
8. Mottillo, S.; Filion, K.B.; Genest, J.; Joseph, L.; Pilote, L.; Poirier, P.; Rinfret, S.; Schiffrin, E.L. and Eisenberg, M.J. (2010) The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J. Am. Coll. Cardiol., 56, 1113-1132.
9. Cave, M.C.; Hurt, R.T.; Frazier, T.H.; Matheson, P.J.; Garrison, R.N.; McClain, C.J. and McClave, S.A. (2008) Obesity, inflammation, and the potential application of pharmaconutrition. Nutr. Clin. Pract., 23, 16-34.
10. Van Horn, L.; McCoin, M.; Kris-Etherton, P.M.; Burke, F.; Carson, J.A.; Champagne, C.M.; Karmally, W. and Sikand, G. (2008) The evidence for dietary prevention and treatment of cardiovascular disease. J. Am. Diet. Assoc., 108, 287-331.
11. Eilat-Adar, S. and Goldbourt, U. (2010) Nutritional recommendations for preventing coronary heart disease in women: evidence concerning whole foods and supplements. Nutr. Metab. Cardiovasc. Dis., 20, 459-466.
12. de Lorgeril, M. and Salen, P. (2008) The Mediterranean diet: rationale and evidence for its benefit. Curr. Atheroscler. Rep.,10, 518-522.
13. Jiménez-Gómez, Y.; Marín, C.; Peérez-Martínez, P.; Hartwich, J.; Malczewska-Malec, M.; Golabek, I.; Kiec-Wilk, B.; Cruz-Teno, C.; Rodríguez, F.; Gómez, P.; Gómez-Luna, M.J.; Defoort, C.; Gibney, M.J.; Pérez-Jiménez, F.; Roche, H.M. and López-Miranda, J. (2010) A low-fat, high-complex carbohydrate diet supplemented with long-chain (n-3) fatty acids alters the postprandial lipoprotein profile in patients with metabolic syndrome. J. Nutr., 140, 1595-1601.
14. Topping, D.L. and Clifton, P.M. (2001) Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol. Rev., 81, 1031-1064.
15. North, C.J.; Venter, C.S. and Jerling, J.C. (2009) The effects of dietary fibre on C-reactive protein, an inflammation marker predicting cardiovascular disease. Eur. J. Clin. Nutr., 63, 921-933.
16. Marchioli, R.; Barzi, F.; Bomba, E.; Chieffo, C.; Di Gregorio, D.; Di Mascio, R.; Franzosi, M.G.; Geraci, E.; Levantesi, G.; Maggioni, A.P.; Mantini, L.; Marfisi, R.M.; Mastrogiuseppe, G.; Mininni, N.; Nicolosi, G.L.; Santini, M.; Schweiger, C.; Tavazzi, L.; Tognoni, G.; Tucci, C.; Valagussa, F. and GISSI-Prevenzione Investigators. (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: timecourse analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation, 105, 1897-1903.
17. He, K. (2009) Fish, long-chain omega-3 polyunsaturated fatty acids and prevention of cardiovascular disease--eat fish or take fish oil supplement? Prog. Cardiovasc. Dis., 52, 95-114.
18. Burr, M.L. (2007) Secondary prevention of CHD in UK men: the Diet and Reinfarction Trial and its sequel. Proc. Nutr. Soc., 66, 9-15.
19. Kris-Etherton, P.M.; Harris, W.S., Appel, L.J.; American Heart Association. and Nutrition Committee. (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation, 106, 2747-2757.
20. Baik, I.; Abbott, R.D.; Curb, J.D. and Shin C. (2010) Intake of fish and n-3 fatty acids and future risk of metabolic syndrome. J. Am. Diet. Assoc., 110, 1018-1026.
21. Ortega, R.M.; Palencia, A. and Lopez-Sobaler, A.M. (2006) Improvement of cholesterol levels and reduction of cardiovascular risk via the consumption of phytosterols. Br. J. Nutr., 96 Suppl 1, S89-S93.
22. AbuMweis, S.S. and Jones, P.J. (2008) Cholesterol-lowering effect of plant sterols. Curr. Atheroscler. Rep., 10, 467-472.
23. Konstantinidou, V.; Covas, M.I.; Munoz-Aguayo, D.; Khymenets, O.; de la Torre, R.; Saez, G.; Tormos Mdel, C.; Toledo, E.; Marti, A.; Ruiz-Gutierrez, V.; Ruiz Mendez, M.V. and Fito, M. (2010) In vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: a randomized controlled trial. FASEB J., 24, 2546-2557.
24. Ros, E.; Tapsell, L.C. and Sabate, J. (2010) Nuts and berries for heart health. Curr. Atheroscler. Rep., 12, 397-406.
25. Das, S. and Das, D.K. (2007) Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat. Cardiovasc. Drug Discov., 2, 133-138.
26. Grove, K.A. and Lambert, J.D. (2010) Laboratory, epidemiological, and human intervention studies show that tea (Camellia sinensis) may be useful in the prevention of obesity. J. Nutr., 140, 446-453.
27. Kris-Etherton, P.M.; Harris, W.S.; Appel, L.J.; AHA Nutrition Committee. and American Heart Association. (2003) Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler. Thromb. Vasc. Biol., 23, 151-152.
28. Weitz, D.; Weintraub, H.; Fisher, E. and Schwartzbard, A.Z. (2010) Fish oil for the treatment of cardiovascular disease. Cardiol. Rev., 18, 258-263.
29. Cicero, A.F.; Ertek, S. and Borghi, C. (2009) Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. Curr. Vasc. Pharmacol., 7, 330-337.
30. Rizza, S.; Tesauro, M.; Cardillo, C.; Galli, A.; Iantorno, M.; Gigli, F.; Sbraccia, P.; Federici, M.; Quon, M.J. and Lauro, D. (2009) Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. Atherosclerosis, 206, 569-574.
31. Gissi, H.F., Tavazzi L.; Maggioni, A.P.; Marchioli, R.; Barlera, S.; Franzosi, M.G.; Latini, R.; Lucci, D.; Nicolosi, G.L.; Porcu, M. and Tognoni, G. (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. Lancet, 372, 1223-1230.
32. Di Minno, M.N.; Tremoli, E.; Tufano, A.; Russolillo, A.; Lupoli, R. and Di Minno, G. (2010) Exploring newer cardioprotective strategies: omega-3 fatty acids in perspective. Thromb. Haemost.,104, 664-680.
33. Abeywardena, M.Y. and Head, R.J. (2001) Longchain n-3 polyunsaturated fatty acids and blood vessel function. Cardiovasc. Res., 52, 361-371.
34. Makris, G.C.; Geroulakos, G.; Makris, M.C.; Mikhailidis, D.P. and Falagas, M.E. (2010) The pleiotropic effects of statins and omega-3 fatty acids against sepsis: a new perspective. Expert. Opin. Investig. Drugs, 19, 809-814.
35. Dimitrow, P.P. and Jawien, M. (2009) Pleiotropic, cardioprotective effects of omega-3 polyunsaturated fatty acids. Mini. Rev. Med. Chem., 9, 1030-1039.
36. M.H. (2006) Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am. J. Cardiol., 98, 27i-33i.
37. Fetterman, J.W. Jr. and Zdanowicz, M.M. (2009) Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am. J. Health Syst. Pharm., 66, 1169-1179.
38. Kelley, D.S.; Siegel, D.; Vemuri, M. and Mackey, B.E. (2007) Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am. J. Clin. Nutr., 86, 324-333.
39. Singer, P.; Shapiro, H.; Theilla, M.; Anbar, R.; Singer, J. and Cohen, J. (2008) Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Int. Care Med., 34, 1580-1592.
40. De Caterina, R.; Massaro, M.; Scoditti, E. and Annunziata, C.M. (2010) Pharmacological modulation of vascular inflammation in atherothrombosis. Ann. N. Y. Acad. Sci., 1207, 23-31.
41. de Leiris, J.; de Lorgeril, M. and Boucher F. (2009) Fish oil and heart health. J. Cardiovasc. Pharmacol., 54, 378-384.
42. McLennan, P.L. and Abeywardena, M.Y. (2005) Membrane basis for fish oil effects on the heart: linking natural hibernators to prevention of human sudden cardiac death. J. Membr. Biol., 206, 85-102.
43. Macchia, A.; Levantesi, G.; Franzosi, M.G.; Geraci, E.; Maggioni, A.P.; Marfisi, R.; Nicolosi, G.L.; Schweiger, C.; Tavazzi, L.; Tognoni, G.; Valagussa, F.; Marchioli, R. and GISSI-Prevenzione Investigators. (2005) Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur. J. Heart Fail., 7, 904-909.
44. Wennberg, M.; Bergdahl, I.A.; Hallmans, G.; Norberg, M.; Lundh, T.; Skerfving, S.; Stromberg, U.; Vessby, B. and Jansson, J.H. (2011) Fish consumption and myocardial infarction: a second prospective biomarker study from northern Sweden. Am. J. Clin. Nutr., 93, 27-36.
45. Das, M.K. and Zipes, D.P. (2010) Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention. J. Cardiovasc. Pharmacol., 55, 438-449.
46. Laposata, M. (1995) Fatty acids. Biochemistry to clinical significance. Am. J. Clin. Pathol., 104, 172-179.
47. Brenna, J.T.; Salem, N. Jr.; Sinclair, A.J. and Cunnane, S.C., (2009) α-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot. Essent. Fatty Acids, 80, 85-91.
48. Fu, Z. and Sinclair, A.J. (2000) Increased alpha-linolenic acid intake increases tissue alpha-linolenic acid content and apparent oxidation with little effect on tissue docosahexaenoic acid in the guinea pig. Lipids, 35, 395-400.
49. Gao, F.; Kiesewetter, D.; Chang, L.; Ma, K.; Bell, J.M.; Rapoport, S.I. and Igarashi, M. (2009) Whole-body synthesis-secretion rates of long-chain n-3 PUFAs from circulating unesterified alphalinolenic acid in unanesthetized rats. J. Lipid Res., 50, 749-758.
50. Gao, F.; Kiesewetter, D.; Chang, L.; Ma, K.; Rapoport, S.I. and Igarashi, M. (2009) Whole-body synthesis secretion of docosahexaenoic acid from circulating eicosapentaenoic acid in unanesthetized rats. J. Lipid Res., 50, 2463-2470.
51. Abeywardena, M.Y.; McMurchie, E.J.; Russell, G.R. and Charnock, J.S. (1984) Species variation in the ouabain sensitivity of cardiac Na+/K+-ATPase: A possible role for membrane lipids. Biochem. Pharmacol., 33, 3649-3654.
52. Tu, W.C.; Cook-Johnson, R.J.; James, M.J.; Mühlhäusler, B.S. and Gibson, R.A. (2010) Omega-3 long chain fatty acid synthesis is regulated more by substrate levels than gene expression. Prostaglandins Leukot. Essent. Fatty Acids, 83, 61-68.
53. Pawlosky, R.J.; Hibbeln, J.R.; Novotny, J.A. and Salem, N. Jr. (2001) Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J. Lipid Res., 42, 1257-1265.
54. Burdge, G.C. and Calder, P.C. (2005) Conversion of alphalinolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod. Nutr. Dev., 45, 581-597.
55. Talahalli, R.R.; Vallikannan, B.; Sambaiah, K. and Lokesh, B.R. (2010) Lower efficacy in the utilization of dietary ALA as compared to preformed EPA + DHA on long chain n-3 PUFA levels in rats. Lipids, 45, 799-808.
56. Goyens, P.L.; Spilker, M.E.; Zock, P.L.; Katan, M.B. and Mensink, R.P. (2005) Compartmental modeling to quantify alpha-linolenic acid conversion after longer term intake of multiple tracer boluses. J. Lipid Res., 46, 1474-1483.
57. Stark, A.H.; Crawford, M.A. and Reifen, R. (2008) Update on alpha-linolenic acid. Nutr. Rev., 66, 326-332.
58. Simopoulos, A.P. (2008) The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp. Biol. Med., (Maywood) 233, 674-688.
59. De Lorgeril, M. (2007) Essential polyunsaturated fatty acids, inflammation, atherosclerosis and cardiovascular diseases. Subcell Biochem., 42, 283-297.
60. Romero, N.; Robert, P.; Masson, L.; Luck, C. and Buschmann, L. (1996) Fatty acid composition and cholesterol content in naturally canned jurel, sardine, salmon, and tuna. Arch. Latinoam. Nutr., 46, 75-77.
61. Yang, H. and Kenny, A. (2007) The role of fish oil in hypertension. Conn. Med., 71, 533-538.
62. Jump, D.B. (2002) The biochemistry of n-3 polyunsaturated fatty acids. J. Biol. Chem., 277, 8755-8758.
63. Welch, A.A.; Shakya-Shrestha, S.; Lentjes, M.A.; Wareham, N.J. and Khaw, K.T. (2010) Dietary intake and status of n-3 polyunsaturated fatty acids in a population of fish-eating and nonfish- eating meat-eaters, vegetarians, and vegans and the precursorproduct ratio of alpha-linolenic acid to long-chain n-3 polyunsaturated fatty acids: results from the EPIC-Norfolk cohort. Am. J. Clin. Nutr., 92, 1040-1051.
64. Chen, Z.Y.; Peng, C.; Jiao, R.; Wong, Y.M.; Yang, N. and Huang, Y. (2009) Anti-hypertensive nutraceuticals and functional foods. J. Agric. Food Chem., 57, 4485-4499.
65. Houston, M.C. (2010) Nutrition and nutraceutical supplements in the treatment of hypertension. Expert Rev. Cardiovasc. Ther., 8, 821-833.
66. Mori, T.A. (2006) Omega-3 fatty acids and hypertension in humans. Clin. Exp. Pharmacol. Physiol., 33, 842-846.
67. Morris, M.C.; Sacks, F. and Rosner, B. (1993) Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation, 88, 523-533.
68. Geleijnse, J.M.; Giltay, E.J.; Grobbee, D.E.; Donders, A.R. and Kok, F.J. (2002) Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J. Hypertens., 20, 1493-1499.
69. L.J.; Miller, E.R. 3rd.; Seidler, A.J. and Whelton, P.K. (1993) Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch. Intern. Med., 153, 1429-1438.
70. [70] Bao, D.Q.; Mori, T.A.; Burke, V.; Puddey, I.B. and Beilin, L.J. (1998) Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. Hypertension, 32, 710-717.
71. Lara, J.J.; Economou, M.; Wallace, A.M.; Rumley, A.; Lowe, G.; Slater, C.; Caslake, M.; Sattar, N. and Lean, M.E. (2007) Benefits of salmon eating on traditional and novel vascular risk factors in young, non-obese healthy subjects. Atherosclerosis, 193, 213-221
72. Cobiac, L.; Nestel, P.J.; Wing, L.M. and Howe, P.R. (1991) Effects of dietary sodium restriction and fish oil supplements on blood pressure in the elderly. Clin. Exp. Pharmacol. Physiol., 18, 265-268.
73. Vandongen, R.; Mori, T.A.; Burke, V.; Beilin, L.J.; Morris, J. and Ritchie, J. (1993) Effects on blood pressure of omega 3 fats in subjects at increased risk of cardiovascular disease. Hypertension, 22, 371-379.
74. Wong, C.Y.; Yiu, K.H.; Li S.W.; Lee, S.; Tam, S.; Lau, C.P. and Tse, H.F. (2010) Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus. Diabet. Med., 27, 54-60.
75. Ramel, A.; Martinez, J.A.; Kiely, M.; Bandarra, N.M. and Thorsdottir, I. (2010) Moderate consumption of fatty fish reduces diastolic blood pressure in overweight and obese European young adults during energy restriction. Nutrition, 26, 168-174.
76. Gutierrez, O.G. Jr.; Ikeda, K.; Nara, Y.; Deguan, G.U. and Yamori, Y. (1994) Fish protein-rich diet attenuates hypertension induced by dietary NG-nitro-L-arginine in normotensive Wistar-Kyoto rats. Clin. Exp. Pharmacol. Physiol., 21, 875-879.
77. Ait-Yahia, D.; Madani, S.; Savelli, J.L.; Prost, J.; Bouchenak, M. and Belleville, J. (2003) Dietary fish protein lowers blood pressure and alters tissue polyunsaturated fatty acid composition in spontaneously hypertensive rats. Nutrition, 19, 342-346.
78. Erkkilä, A.T.; Schwab, U.S.; de Mello, V.D.; Lappalainen, T.; Mussalo, H.; Lehto, S.; Kemi, V.; Lamberg-Allardt, C. and Uusitupa, M.I. (2008) Effects of fatty and lean fish intake on blood pressure in subjects with coronary heart disease using multiple medications. Eur. J. Nutr., 47, 319-328.
79. Massaro, M.; Habib, A.; Lubrano, L.; Del Turco, S.; Lazzerini, G.; Bourcier, T.; Weksler, B.B. and De Caterina, R. (2006) The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. Proc. Natl. Acad. Sci. USA, 103, 15184-15189.
80. Mori, T.A.; Bao, D.Q.; Burke, V.; Puddey, I.B. and Beilin, L.J. (1999) Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension, 34, 253-260.
81. Mori, T.A.; Watts, G.F.; Burke, V.; Hilme, E.; Puddey, I.B. and Beilin, L.J. (2000) Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation, 102, 1264-1269.
82. Calder, P.C. (2006) Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot. Essent. Fatty Acids., 75, 197-202.
83. Kobatake, Y.; Kuroda, K.; Jinnouchi, H.; Nishide, E. and Innami, S. (1984) Differential effects of dietary eicosapentaenoic and docosahexaenoic fatty acids on lowering of triglyceride and cholesterol levels in the serum of rats on hypercholesterolemic diet. J. Nutr. Sci. Vitaminol. (Tokyo)., 30, 357-372.
84. Rambjør, G.S.; Wålen, A.I.; Windsor, S.L. and Harris, W.S. (1996) Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans. Lipids, 31 Suppl, S45-S49.
85. Terano, T.; Kojima, T.; Seya, A.; Tanabe, E.; Hirai, A.; Makuta, H.; Ozawa, A.; Fujita, T.; Tamura, Y.; Okamoto, S. et al. (1989) The effect of highly purified eicosapentaenoic acid in patients with psoriasis. Adv. Prostaglandin Thromboxane Leukot. Res.,19, 610-613.
86. Hirai, A.; Terano, T.; Makuta, H.; Ozawa, A.; Fujita, T.; Tamura, Y. and Yoshida, S. (1989) Effect of oral administration of highly purified eicosapentaenoic acid and docosahexaenoic acid on platelet function and serum lipids in hyperlipidemic patients. Adv. Prostaglandin Thromboxane Leukot. Res., 19, 627-630.
87. Gorjão, R.; Azevedo-Martins, A.K.; Rodrigues, H.G.; Abdulkader, F.; Arcisio-Miranda, M.; Procopio, J. and Curi, R. (2009) Comparative effects of DHA and EPA on cell function. Pharmacol. Ther., 122, 56-64.
88. McLennan, P.; Howe, P.; Abeywardena, M.; Muggli, R.; Raederstorff, D.; Mano, M.; Rayner, T. and Head R. (1996) The cardiovascular protective role of docosahexaenoic acid. Eur. J. Pharmacol., 300, 83-89.
89. Woodman, R.J.; Mori, T.A.; Burke, V.; Puddey, I.B.; Watts, G.F.; Beilin, L.J. (2002) Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am. J. Clin. Nutr., 76, 1007-1015.
90. Singer, P.; Melzer, S.; Goschel, M. and Augustin, S. (1990) Fish oil amplifies the effect of propranolol in mild essential hypertension. Hypertension, 16, 682-691.
91. Lungershausen, Y.K.; Abbey, M.; Nestel, P.J. and Howe, P.R. (1994) Reduction of blood pressure and plasma triglycerides by omega-3 fatty acids in treated hypertensives. J. Hypertens., 12, 1041-1045.
92. Howe, P.R.; Lungershausen, Y.K.; Cobiac, L.; Dandy, G. and Nestel, P.J. (1994) Effect of sodium restriction and fish oil supplementation on BP and thrombotic risk factors in patients treated with ACE inhibitors. J. Hum. Hypertens., 8, 43-49.
93. Wang, S.; Ma, A.Q.; Song, S.W.; Quan, Q.H.; Zhao, X.F. and Zheng, X.H. (2008) Fish oil supplementation improves large arterial elasticity in overweight hypertensive patients. Eur. J. Clin. Nutr., 62, 1426-1431.
94. Taddei, S.; Ghiadoni, L.; Virdis, A.; Versari, D. and Salvetti, A. (2003) Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies. Curr. Pharm. Des., 9, 2385-2402.
95. Stebbins, C.L.; Stice, J.P.; Hart, C.M.; Mbai, F.N. and Knowlton, A.A. (2008) Effects of dietary decosahexaenoic acid (DHA) on eNOS in human coronary artery endothelial cells. J. Cardiovasc. Pharmacol. Ther., 13, 261-268.
96. De Caterina, R.; Massaro, M.; Scoditti, E. and Annunziata, C.M. (2010) Pharmacological modulation of vascular inflammation in atherothrombosis. Ann. N. Y. Acad. Sci., 1207, 23-31.
97. Higashi, Y.; Noma, K.; Yoshizumi, M. and Kihara, Y. (2009) Endothelial function and oxidative stress in cardiovascular diseases. Circ. J., 73, 411-418.
98. Hashimoto, M.; Shinozuka, K.; Gamoh, S.; Tanabe, Y.; Hossain, M.S.; Kwon, Y.M.; Hata, N.; Misawa, Y.; Kunitomo, M. and Masumura, S. (1999) The hypotensive effect of docosahexaenoic acid is associated with the enhanced release of ATP from the caudal artery of aged rats. J. Nutr., 129, 70-76.
99. Monahan, K.D.; Wilson, T.E. and Ray, C.A. (2004) Omega-3 fatty acid supplementation augments sympathetic nerve activity responses to physiological stressors in humans. Hypertension, 44, 732-738.
100. Schenk, S.; Saberi, M. and Olefsky, J.M. (2008) Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest., 118, 2992-3002.
101. Fedor, D. and Kelley, D.S. (2009) Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr. Opin. Clin. Nutr. Metab. Care, 12, 138-146.
102. Feskens, E.J.; Bowles, C.H. and Kromhout, D. (1991) Inverse association between fish intake and risk of glucose intolerance in normoglycemic elderly men and women. Diabetes Care, 14, 935-941.
103. Lombardo, Y.B. and Chicco, A.G. (2006) Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J. Nutr. Biochem., 17, 1-13.
104. Griffin, M.D.; Sanders, T.A.; Davies, I.G.; Morgan, L.M.; Millward, D.J.; Lewis, F.; Slaughter, S.; Cooper, J.A.; Miller, G.J. and Griffin, B.A. (2006) Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 y: the OPTILIP Study. Am. J. Clin. Nutr., 84, 1290-1298.
105. Kabir, M.; Skurnik, G.; Naour, N.; Pechtner, V.; Meugnier, E.; Rome, S.; Quignard-Boulangé, A.; Vidal, H.; Slama, G.; Clément, K.; Guerre-Millo, M. and Rizkalla, S.W. (2007) Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am. J. Clin. Nutr., 86, 1670-1679.
106. Giacco, R.; Cuomo, V.; Vessby, B.; Uusitupa, M.; Hermansen, K.; Meyer, B.J.; Riccardi, G.; Rivellese, A.A. and KANWU Study Group. (2007) Fish oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy people: is there any effect of fish oil supplementation in relation to the type of background diet and habitual dietary intake of n-6 and n-3 fatty acids? Nutr. Metab. Cardiovasc. Dis., 17, 572-580.
107. Tsitouras, P.D.; Gucciardo, F.; Salbe, A.D.; Heward, C. and Harman, S.M. (2008) High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults. Horm. Metab. Res., 40, 199-205.
108. Bloedon, L.T.; Balikai, S.; Chittams, J.; Cunnane, S.C.; Berlin, J.A.; Rader, D.J. and Szapary, P.O. (2008) Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial. J. Am. Coll. Nutr., 27, 65-74.
109. Ramel, A.; Martinéz, A.; Kiely, M.; Morais, G.; Bandarra, N.M. and Thorsdottir, I. (2008) Beneficial effects of long-chain n-3 fatty acids included in an energy-restricted diet on insulin resistance in overweight and obese European young adults. Diabetologia, 51, 1261-1268.
110. Krebs, J.D.; Browning, L.M.; McLean, N.K.; Rothwell, J.L.; Mishra, G.D.; Moore, C.S. and Jebb, S.A. (2006) Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. Int. J. Obes. (Lond)., 30, 1535-1544.
111. Browning, L.M.; Krebs, J.D.; Moore, C.S.; Mishra, G.D.; O'Connell, M.A. and Jebb, S.A. (2007) The impact of long chain n- 3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes. Metab., 9, 70-80.
112. Martín de Santa Olalla, L., Sánchez, M.F.J. and Vaquero, M.P. (2009) N-3 fatty acids in glucose metabolism and insulin sensitivity. Nutr. Hosp., 24, 113-127.
113. Nettleton, J.A., and Katz, R., (2005) n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J. Am. Diet. Assoc., 105, 428-440.
114. Rudkowska, I. (2010) Fish oils for cardiovascular disease: Impact on diabetes. Maturitas, 67, 25-28.
115. Glauber, H.; Wallace, P.; Griver, K. and Brechtel, G. (1988) Adverse metabolic effect of omega-3 fatty acids in non-insulindependent diabetes mellitus. Ann. Intern. Med., 108, 663-668.
116. Friday, K.E.; Childs, M.T.; Tsunehara, C.H.; Fujimoto, W.Y.; Bierman, E.L. and Ensinck, J.W. (1989) Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes. Diabetes Care, 12, 276-281.
117. Rivellese, A.A.; Maffettone, A.; Iovine, C.; Di Marino, L.; Annuzzi, G.; Mancini, M. and Riccardi, G. (1996) Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care, 19, 1207-1213.
118. Popp-Snijders, C.; Schouten J.A.; Heine, R.J.; van der Meer, J. and van der Veen, E.A. (1987) Dietary supplementation of omega-3 polyunsaturated fatty acids improves insulin sensitivity in noninsulin-dependent diabetes. Diabetes Res., 4, 141-147.
119. Friedberg, C.E.; Janssen M.J.; Heine, R.J. and Grobbee, D.E. (1998) Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care, 21, 494-500.
120. Montori, V.M.; Farmer, A.; Wollan, P.C. and Dinneen, S.F. (2000) Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care, 23, 1407-1415.
121. American Diabetes Association. (2002) Eveidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care, 25, S50-S60.
122. Kris-Etherton, P.M.; Harris, W.S.; Appel, L.J.; AHA Nutrition Committee. and American Heart Association. (2003) Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler. Thromb. Vasc. Biol., 23, 151-152.
123. Hartweg, J.; Perera, R.; Montori, V.; Dinneen, S.; Neil, H.A. and Farmer, A. (2008) Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst. Rev., 23, CD003205.
124. Hartweg, J.; Farmer, A.J.; Holman, R.R. and Neil, A. (2009) Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr. Opin. Lipidol., 20, 30-38.
125. N.D.; Othman, R.A.; Suh, M. and Moghadasian, M.H. (2009) A systemic review of the roles of n-3 fatty acids in health and disease. J. Am. Diet. Assoc., 109, 668-679.
126. Andersson, A.; Nälsén, C.; Tengblad, S. and Vessby, B. (2002) Fatty acid composition of skeletal muscle reflects dietary fat composition in humans. Am. J. Clin. Nutr., 76, 1222-1229.
127. Borkman, M.; Storlien, L.H.; Pan, D.A.; Jenkins, A.B.; Chisholm, D.J. and Campbell, L.V. (1993) The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N. Engl. J. Med., 328, 238-244.
128. Clore, J.N.; Li, J.; Gill, R.; Gupta, S.; Spencer, R.; Azzam, A.; Zuelzer, W.; Rizzo, W.B. and Blackard, W.G. (1998) Skeletal muscle phosphatidylcholine fatty acids and insulin sensitivity in normal humans. Am. J. Physiol., 275, E665-E670.
129. Pan, D.A.; Lillioja, S.; Milner, M.R.; Kriketos, A.D.; Baur, L.A.; Bogardus, C. and Storlien, L.H. (1995) Skeletal muscle membrane lipid composition is related to adiposity and insulin action. J. Clin. Invest., 96, 2802-2808.
130. Vessby, B.; Tengblad, S. and Lithell, H. (1994) Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70-year-old men. Diabetologia, 37, 1044-1050.
131. Kriketos, A.D.; Pan, D.A.; Lillioja, S.; Cooney, G.J.; Baur, L.A.; Milner, M.R.; Sutton, J.R.; Jenkins, A.B.; Bogardus, C. and Storlien, L.H. (1996) Interrelationships between muscle morphology, insulin action, and adiposity. Am. J. Physiol., 270, R1332-1339.
132. Vessby, B.; Uusitupa, M.; Hermansen, K.; Riccardi, G.; Rivellese, A.A.; Tapsell, L.C.; Nälsén, C.; Berglund, L.; Louheranta, A.; Rasmussen, B.M.; Calvert, G.D.; Maffetone, A.; Pedersen, E.; Gustafsson, I.B.; Storlien, L.H. and KANWU Study. (2001) Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. Diabetologia, 44, 312-319.
133. Potenza, M.V. and Mechanick, J.I. (2009) The metabolic syndrome: definition, global impact, and pathophysiology. Nutr. Clin. Pract., 24, 560-577.
134. Buckley, J.D. and Howe, P.R. (2009) Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. Obes. Rev., 10, 648-659.
135. Barre, D.E. (2007) The role of consumption of alpha-linolenic, eicosapentaenoic and docosahexaenoic acids in human metabolic syndrome and type 2 diabetes-a mini-review. J. Oleo. Sci., 56, 319-325.
136. Robinson, L.E.; Buchholz, A.C. and Mazurak, V.C. (2007) Inflammation, obesity, and fatty acid metabolism: influence of n-3 polyunsaturated fatty acids on factors contributing to metabolic syndrome. Appl. Physiol. Nutr. Metab., 32, 1008-1024.
137. Tai, C.C. and Ding, S.T. (2010) N-3 polyunsaturated fatty acids regulate lipid metabolism through several inflammation mediators: mechanisms and implications for obesity prevention. J. Nutr. Biochem., 21, 357-363.
138. Baik, I.; Abbott, R.D.; Curb, J.D. and Shin, C. (2010) Intake of fish and n-3 fatty acids and future risk of metabolic syndrome. J. Am. Diet. Assoc., 110, 1018-1026.
139. Watts, G.F.; Ooi, E.M. and Chan, D.C. (2009) Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. Pharmacol. Ther., 123, 281-291.
140. Chan, D.C. and Watts, G.F. (2008) Pharmacological regulation of dyslipoproteinaemia in insulin resistant states. Curr. Vasc. Pharmacol., 6, 67-77.
141. Chan, D.C. and Watts, G.F. (2011) Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert. Opin. Pharmacother., 12, 13-30.
142. Chan, D.C.; Barrett, P.H. and Watts, G.F. (2004) Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies. Clin. Biochem. Rev., 25, 31-48.
143. Chan, D.C.; Watts, G.F.; Mori, T.A.; Barrett, P.H.; Redgrave, T.G. and Beilin, L.J. (2003) Randomized control trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnanats in men with visceral obesity. Am. J. Clin. Nutr., 77, 300-307.
144. Watts, G.F. and Chan, D.C. (2010) Mechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes. Athersoclerosis Suppl., 11, 61-64.
145. Chan, D.C.; Watts, G.F.; Barrett, P.H.; Beilin, L.J.; Redgrave, T.G. and Mori, T.A. (2002) Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulinresistant obese male subjects with dyslipidemia. Diabetes, 51, 2377-2386.
146. Chan, D.C.; Nguyen, M.N.; Watts, G.F.; Ooi, E.M. and Barrett, P.H. (2010) Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. Am. J. Clin. Nutr., 91, 900-906.
147. Van Gaal, L.F.; Mertens, I.L. and De Block, C.E. (2006) Mechanisms linking obesity with cardiovascular disease. Nature, 444, 875-880.
148. Lau, D.C.; Dhillon, B.; Yan, H.; Szmitko, P.E. and Verma, S. (2005) Adipokines: molecular links between obesity and atheroslcerosis. Am. J. Physiol. Heart Circ. Physiol., 288, H2031-2041.
149. Matsuzawa, Y.; Shimomura, I.; Kihara, S. and Funahashi, T. (2003) Importance of adipocytokines in obesity-related diseases. Horm. Res., 60, 56-59.
150. Matsuzawa, Y.; Funahashi, T.; Kihara, S. and Shimomura, I. (2004) Adiponectin and Metabolic Syndrome. Arterioscler. Thromb. Vasc. Biol., 24, 29-33.
151. Ouchi, N.; Kihara, S.; Funahashi, T.; Matsuzawa, Y. and Walsh, K. (2003) Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol., 14, 561-566.
152. Xu, A.; Wang, Y.; Lam, K.S. and Vanhoutte, P.M. (2010) Vascular actions of adipokines molecular mechanisms and therapeutic implications. Adv. Pharmacol., 60, 229-255.
153. Okamoto, Y.; Kihara, S.; Funahashi, T.; Matsuzawa, Y. and Libby, P. (2006) Adiponectin: a key adipocytokine in metabolic syndrome. Clin. Sci. (Lond)., 110, 267-278.
154. Li, F.Y.; Cheng, K.K.; Lam, K.S.; Vanhoutte, P.M. and Xu, A. (2010) Cross-talk between adipose tissue and vasculature: role of adiponectin. Acta Physiol. (Oxf)., Nov 10.doi: 10.1111/j.1748- 1716.2010.02216.x.[Epub ahead of print]
155. Guebre-Egziabher, F.; Rbasa-Lhoret, R.; Bonnet, F.; Bastard, J.P.; Desage, M.; Skilton, M.R.; Vidal, H. and Laville, M. (2008) Nutritional intervention to reduce the n-6/n-3 fatty acid ratio increases adiponectin concentration and fatty acid oxidation in healthy subjects. Eur. J. Clin. Nutr., 62, 1287-1293.
156. Kratz, M.; Swarbrick, M.M.; Callahan, H.S.; Matthys, C.C.; Havel, P.J. and Weigle, D.S. (2008) Effect of dietary n-3 polyunsaturated fatty acids on plasma total and high-molecular-weight adiponectin concentrations in overweight to moderately obese men and women. Am. J. Clin. Nutr., 87, 347-353.
157. Kondo, K.; Morino, K.; Nishio, Y.; Kondo, M.; Fuke, T.; Ugi, S.; Iwakawa, H.; Kashiwagi, A. and Maegawa, H. (2010) Effects of a fish-based diet on the serum adiponectin concentration in young, non-obese, healthy Japanese subjects. J. Atheroscler. Thromb., 17, 628-637.
158. Kopecky, J.; Rossmeisl, M.; Flachs, P.; Kuda, O.; Brauner, P.; Jilkova, Z.; Stankova, B.; Tvrzicka, E. and Bryhn, M. (2009) n-3 PUFA: bioavailability and modulation of adipose tissue function. Proc. Nutr. Soc., 68, 361-369.
159. Mori, T.A.; Woodman, R.J.; Burke, V.; Puddey, I.B.; Croft, K.D. and Beilin, L.J. (2003) Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic. Biol. Med., 35, 772-781.
160. Mas, E.; Woodman, R.J.; Burke, V.; Puddey, I.B.; Beilin, L.J.; Durand, T. and Mori, T.A. (2010) The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: Results from two placebo-controlled interventions. Free Radic. Res., 44, 983-990.
161. Dimitrow, P.P. and Jawien, M. (2009) Pleiotropic, cardioprotective effects of omega-3 polyunsaturated fatty acids. Mini Rev. Med. Chem., 9, 1030-1039.
162. Tsitouras, P.D.; Gucciardo, F.; Salbe, A.D.; Heward, C. and Harman, S.M. (2008) High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults. Horm. Metab. Res., 40, 199-205.
163. Kelley, D.S.; Siegel, D.; Fedor, D.M.; Adkins, Y. and Mackey, B.E. (2009) DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J. Nutr., 139, 495-501.
164. Ramel, A.; Martinez, J.A.; Kiely, M.; Bandarra, N.M. and Thorsdottir, I. (2010) Effects of weight loss and seafood consumption on inflammation parameters in young, overweight and obese European men and women during 8 weeks of energy restriction. Eur. J. Clin. Nutr., 64, 987-993.
165. Abeywardena, M.Y.; Leifert, W.R.; Warnes, K.E.; Varghese, J.N. and Head, R.J. (2009) Cardiovascular biology of interleukin-6. Curr. Pharm. Des., 15, 1809-1821.
166. Kalogeropoulos, N.; Panagiotakos, D.B.; Pitsavos, C.; Chrysohoou, C.; Rousinou, G.; Toutouza, M. and Stefanadis, C. (2010) Unsaturated fatty acids are inversely associated and n-6/n-3 ratios are positively related to inflammation and coagulation markers in plasma of apparently healthy adults. Clinica Chimica Acta, 411, 584-591.
167. Zhao, Y.T.; Shao, L.; Teng, L.L.; Hu, B.; Luo, Y.; Yu, X.; Zhang, D.F. and Zhang, H. (2009) Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure. J. Int. Med. Res., 37, 1831-1841.
168. Trøseid, M.; Arnesen, H.; Hjerkinn, E.M. and Seljeflot, I. (2009) Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men. Metab. Clin. Exp., 58, 1543-1549.
169. Abeywardena, M.; Nichols, P. and Singh, S. (2005) Future Omega 3s. The World of Food Ingredients, 2005; 50-54.
170. Harris, W.S.; Lemke, S.L.; Hansen, S.N.; Goldstein, D.A.; DiRienzo, M.A.; Su, H.; Nemeth, M.A.; Taylor, M.L.; Ahmed, G. and George, C. (2008) Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker. Lipids, 43, 805-811.
171. Lemke, S.L.; Vicini, J.L.; Su, H.; Goldstein, D.A.; Nemeth, M.A.; Krul, E.S. and Harris, W.S. (2010) Dietary intake of stearidonic acid-enriched soybean oil increases the omega-3 index: randomized, double-blind clinical study of efficacy and safety. Am. J. Clin. Nutr., 92, 766-775.
172. Nichols, P.D.; Petrie, J. and Singh, S. (2010) Long-chain omega-3 oils - an update on sustainable sources. Nutrients, 2, 572-585.
173. Petrie, J.R.; Shrestha, P.; Mansour, M.P.; Nichols, P.D.; Liu, Q. and Singh, S.P. (2010) Metabolic engineering of omega-3 long-chain polyunsaturated fatty acids in plants using an acyl-CoA Delta6-desaturase with omega3-preference from the marine microalga Micromonas pusilla. Metab Eng., 12, 233-240.
174. Wijesundara, C.; Kitessa, S.; Abeywardena, M.; Bignell, W. and Nichols, P.D. (2011) Long-chain omega-3 oils: current and future supplies, food and feed applications, and stability. Lipid Technol., 23, 55-58.